| Filed On | Filing |
|---|---|
| 10 Nov 2026 | SCHEDULE 13G |
| 02 Nov 2026 |
Form 4: Grogan Jane, Head of Research
Received 695 shares by exercise or conversion · Gave up 345 shares to cover exercise price or tax ($87.5K) |
| 28 Oct 2026 | 10-Q |
| 28 Oct 2026 |
8-K: Results of Operations and Financial Condition
Biogen Inc. (Nasdaq: BIIB) today reported third quarter 2026 financial results. |
| 05 Oct 2026 |
Form 4: Godbout Sean, Chief Accounting Officer
Granted 985 Restricted Stock Unit · Received 27 shares by exercise or conversion · Gave up 8 shares to cover exercise price or tax ($1.76K) |
| 03 Sep 2026 |
Form 4: Parini Michael, Chief Legal Officer
Granted 7,405 Restricted Stock Unit |
| 12 Aug 2026 |
Form 3: Parini Michael, Chief Legal Officer
No securities owned |
| 06 Aug 2026 | SCHEDULE 13G/A |
| 05 Aug 2026 |
Form 4: Minor Lloyd, Director
Sold 593 shares ($121K) · Sold 593 shares ($119K) |
| 04 Aug 2026 | 144 |
| 03 Aug 2026 | 144 |
| 29 Jul 2026 | 10-Q |
| 29 Jul 2026 |
8-K: Results of Operations and Financial Condition
Biogen Inc. (Nasdaq: BIIB) today reported second quarter 2026 financial results. |
| 01 Jul 2026 |
8-K: Results of Operations and Financial Condition
Biogen Inc. (Biogen) expects that its GAAP and non-GAAP results for the second quarter of 2026 will include acquired in-process research and development, upfront and milestone expense of approximately $164 million on a pre-tax basis. The... |
| 11 Jun 2026 |
Form 4: Hawkins William A, Director
Received 1,505 shares as a grant or award |
| 11 Jun 2026 |
Form 4: Sherwin Stephen A, Director
Received 1,505 shares as a grant or award |
| 11 Jun 2026 |
Form 4: Rowinsky Eric K, Director
Received 1,505 shares as a grant or award |
| 11 Jun 2026 |
Form 4: Mantas Jesus B, Director
Received 1,505 shares as a grant or award |
| 11 Jun 2026 |
Form 4: Langer Susan, Director
Received 1,505 shares as a grant or award |
| 11 Jun 2026 |
Form 4: Patolawala Monish D, Director
Received 1,505 shares as a grant or award |
Loading...